ClinicalTrials.gov
public full text
Public Domain
A Study of TQB3820 in Patients With Hematological Malignancies
TQB3820 is a novel cereblon-modulating agent. Upon binding to cereblon, a substrate receptor in the cullin4 E3 ligase complex, TQB3820 promotes recruitment, ubiquitination, and subsequent proteasomal degradation of the hematopoietic transcription factors Ikaros (IKZF1) and Aiolos (IKZF3). Modulation of Aiolos and Ikaros expression has the potential to correct multiple aspects of the immune dysregulation mediated by B cells.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- EZH2 inhibition overcomes immunomodulatory drug resistance in multiple myeloma via a cereblon-dependent pathway#379314
- A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer#825503
- New Biomarkers in Auto-immune Encephalitis and Neurological Paraneoplastic Syndromes#121345
- A chemogenetic CRISPR knockout screen identifies a ubiquitin-mediated calcineurin-BMP pathway relay in T cell activation#435627
- cPLA 2 α targeting to exosomes connects nuclear deformation to LTB 4 -signaling during neutrophil chemotaxis#1133705
Record · ID 812569
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive